ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
다우존스 지수
38,834.86
0.15%
Bitcoin
64,808.48
-0.51%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Gossamer Bio Inc (GOSS)

  7. Gossamer Bio Inc (GOSS) 뉴스

GOSS

Gossamer Bio (GOSS)

Gossamer Bio Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:GOSS
일자시간출처헤드라인심볼기업
2024/06/1105:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2024/06/0805:30Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
2024/06/0710:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2024/05/1505:01Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceNASDAQ:GOSSGossamer Bio Inc
2024/05/1105:30Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
2024/05/0805:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2024/05/0805:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GOSSGossamer Bio Inc
2024/05/0805:01Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
2024/05/0620:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2024/05/0620:30Business WireGossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsNASDAQ:GOSSGossamer Bio Inc
2024/05/0321:02Business WireGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineNASDAQ:GOSSGossamer Bio Inc
2024/03/1220:31Business WireGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
2024/03/0521:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GOSSGossamer Bio Inc
2024/03/0521:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GOSSGossamer Bio Inc
2024/03/0521:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2024/03/0521:31Business WireGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
2024/03/0506:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2024/01/0906:01Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
2024/01/0507:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2024/01/0507:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2024/01/0507:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2023/12/1406:01Business WireGossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023NASDAQ:GOSSGossamer Bio Inc
2023/12/0607:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2023/12/0607:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
2023/12/0606:01Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
2023/12/0521:01Business WireGossamer Bio Appoints Bob Smith as Chief Commercial OfficerNASDAQ:GOSSGossamer Bio Inc
2023/11/3006:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2023/11/2921:01Business WireGossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
2023/11/2806:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
2023/11/2309:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
 검색 관련기사 보기:NASDAQ:GOSS

최근 히스토리

NASDAQ
HYW
Hywin
COIN
MELONNETH
MELON
LSE
MAG7
5x Long Mag7
USOTC
SENEM
Seneca Foods (PK)
LSE
0LWG
Weyerhaeuser
LBNK
WSGUSDT
Wall Street Games
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유